Fineline Cube

Follow:
14754 Articles
Regeneron's Eylea HD Receives FDA Priority Review for Macular Edema Treatment
CompanyDrug

Regeneron’s Eylea HD Receives FDA Priority Review for Macular Edema Treatment

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL
CompanyDrug

BRL Medicine Secures IND Approval for BRL-301 CAR-T Therapy in R/R B-NHL

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment
CompanyDeals

Sanofi Licenses First-in-Class BsAbs from Earendil Labs for Autoimmune and IBD Treatment

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment
Company

Bayer Commissions Pennsylvania Facility Expansion After $44 Million Investment

Takeda's Adzynma, BeiGene's Sonrotoclax, and Avistone's Andatinib Set for Priority Review in China
CompanyDrug

Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China

Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102
CompanyDeals

Velavigo and Ollin Biosciences Ink licensing Deal for First-in-Class BsAb VBS-102

Eli Lilly's Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes
CompanyDrug

Eli Lilly’s Orforglipron Meets Primary Endpoint in Phase III ACHIEVE-1 Trial for Type 2 Diabetes

3SBio's 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China
CompanyDrug

3SBio’s 707 Bispecific Antibody Receives BTD for First-Line NSCLC in China

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development
CompanyDeals

NeuShen Therapeutics Closes Series A Funding for CNS Disorder Drug Development

La Prairie Holistic Health's Functional Nutrient Product Approved in Hainan Pilot Zone
Company

La Prairie Holistic Health’s Functional Nutrient Product Approved in Hainan Pilot Zone

GSK's Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59
CompanyDrug

GSK’s Arexvy RSV Vaccine Receives Favorable ACIP Vote for Adults Aged 50-59

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy
CompanyDrug

Gene Cradle Gains NMPA Approval for Phase III Trial of GC101 in Type II 5q Spinal Muscular Atrophy